CEA-Leti project to use nano-delivery systems to treat IBD
CEA-Leti, a French research and technology organization has started a new project designed to develop a nanocarrier-based approach to improve the treatment of inflammatory bowel disease (IBD).
The delivering of nano-pharmaceuticals through Biological Barriers project, known as BIBA, involves eight partners in France, Germany, Spain and Switzerland. BIBA is coordinated by CEA-Leti as part of its research program on organic nanocarriers and delivery systems for clinical applications like molecular imaging and drug delivery.
The three-year study is designed to develop an anti-inflammatory corticoid and/or an immunosuppressant encapsulated within a biodegradable nanocarrier for improved treatment of IBD and reduced side effects, said the organization.
BIBA will investigate local delivery of encapsulated corticosteroids and immunosuppressants using two types of organic biodegradable nanocarriers to prevent side effects. In vitro experiments will be performed on a lab model of healthy and pathological epithelium to screen the most relevant nano-pharmaceuticals. Formulations will then be evaluated in vivo in appropriate rodent colitis models. Non-invasive MRI and optical fluorescence in combination with histological analysis will be used to monitor the effect of the therapy on the inflamed mucosa.
The BIBA study is funded by the European program ERANET EuroNanoMed.
The delivering of nano-pharmaceuticals through Biological Barriers project, known as BIBA, involves eight partners in France, Germany, Spain and Switzerland. BIBA is coordinated by CEA-Leti as part of its research program on organic nanocarriers and delivery systems for clinical applications like molecular imaging and drug delivery.
The three-year study is designed to develop an anti-inflammatory corticoid and/or an immunosuppressant encapsulated within a biodegradable nanocarrier for improved treatment of IBD and reduced side effects, said the organization.
BIBA will investigate local delivery of encapsulated corticosteroids and immunosuppressants using two types of organic biodegradable nanocarriers to prevent side effects. In vitro experiments will be performed on a lab model of healthy and pathological epithelium to screen the most relevant nano-pharmaceuticals. Formulations will then be evaluated in vivo in appropriate rodent colitis models. Non-invasive MRI and optical fluorescence in combination with histological analysis will be used to monitor the effect of the therapy on the inflamed mucosa.
The BIBA study is funded by the European program ERANET EuroNanoMed.